Dividend Power Score
A single, comprehensive score designed to measure the true strength of a company’s dividend.
This score combines three essential pillars of dividend quality:
Consistency – Measures how reliable the dividend has been over time, focusing on payment history, stability, and the absence of cuts or suspensions.
Payability – Assesses the company’s financial ability to sustain its dividend, taking into account cash flow, earnings coverage, balance sheet strength, and overall financial health.
Growth – Evaluates the long-term growth of both the dividend and the company’s share price, highlighting businesses that consistently increase payouts while creating shareholder value.
Higher scores identify companies that have historically delivered dependable income alongside sustained dividend growth and long-term capital appreciation.
Company Overview
Silo Pharma, Inc. is a clinical-stage biopharmaceutical company focused on developing novel therapeutics for neurological disorders, psychiatric conditions, and chronic pain. The company operates within the biotechnology and pharmaceutical research industries, with an emphasis on compounds derived from or inspired by psychedelic substances and other non-traditional drug modalities. Silo Pharma does not currently have FDA-approved products and generates no commercial revenue, with activities centered on research and development.
The company’s primary business involves advancing a pipeline of preclinical and early clinical drug candidates targeting indications such as depression, post-traumatic stress disorder (PTSD), Alzheimer’s disease, multiple sclerosis–related pain, and other central nervous system conditions. Silo Pharma positions itself as a translational research company, leveraging academic collaborations to move early scientific discoveries toward clinical application. Founded in 2020, the company became publicly traded via a reverse merger and has since focused on building an intellectual property portfolio and advancing multiple investigational programs in parallel.
Business Operations
Silo Pharma operates as a single-reportable-segment company focused on drug discovery and development, with internal operations concentrated on program management, regulatory planning, and intellectual property development. Research activities are primarily conducted through sponsored research agreements and licensing arrangements with academic institutions rather than through large internal laboratories, reflecting an asset-light operating model common among early-stage biotechnology firms.
The company’s pipeline includes drug candidates utilizing intranasal delivery platforms, oral therapeutics, and peptide-based technologies. Silo Pharma controls development rights to these assets through exclusive licenses and patents filed or obtained via its research partners. Operations are primarily domestic, with research collaborations in the United States, and no material international commercial operations reported. Data on formal subsidiaries or joint ventures is inconclusive based on available public sources.
Strategic Position & Investments
Strategically, Silo Pharma is focused on advancing multiple early-stage assets toward IND-enabling studies and early clinical trials, while expanding and defending its intellectual property estate. Growth initiatives center on progressing its lead candidates through regulatory milestones, securing additional academic partnerships, and potentially acquiring or licensing complementary technologies that align with its CNS and pain-management focus.
The company has announced investments in sponsored research programs with U.S.-based universities and medical research institutions, which serve as a key component of its innovation strategy. While Silo Pharma has referenced interest in emerging sectors such as psychedelic-assisted therapeutics and novel drug delivery systems, its investments remain limited to early-stage R&D rather than revenue-generating acquisitions. Any future acquisitions or late-stage clinical investments have not been conclusively verified in public disclosures.
Geographic Footprint
Silo Pharma is headquartered in the United States, with corporate operations and management based domestically. Its research footprint is also primarily U.S.-focused, reflecting the location of its academic collaborators and regulatory pathway through the U.S. Food and Drug Administration.
The company does not currently report a significant operational presence outside North America, nor does it disclose international manufacturing or commercial infrastructure. International influence is limited to the global scope of its patent filings and the potential future applicability of its drug candidates in non-U.S. markets, subject to regulatory approvals.
Leadership & Governance
Silo Pharma is led by an executive team with experience in biotechnology commercialization, corporate finance, and public company management. Leadership emphasizes a strategy of capital efficiency, intellectual property development, and risk-managed advancement of multiple therapeutic programs in parallel, as outlined in company filings and investor communications.
Key executives identified in public disclosures include:
- Douglas K. Gordon – Chief Executive Officer
- Michael Hartman – Chief Financial Officer
Information regarding additional executive officers, founders, or board-level leadership varies across disclosures; data inconclusive based on available public sources. Governance practices are consistent with U.S. public company requirements, with oversight provided through a board of directors and standard audit and compensation committees.